RUNX2 and prostate carcinoma: In a complementary study, Senbanjo et al. elucidated that within PC3 prostate cancer cells, RUNX2 forms a co-transcriptional complex with CD44-ICD, resulting in the upregulation of metastasis-associated genes and thereby promoting cellular invasion and migration [133].